Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | CDK4 | P11802 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | CCND1 | P24385 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 3/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7954957 | 0.89 | SMN1; SMN2 (0.49) | KMT2AALDH1A1MEN1ALOX15TSHR | |
| SCHEMBL30662376 | 0.78 | ALDH1A1 (0.57) | KMT2AALDH1A1MEN1USP2CDK4 | |
| SCHEMBL11641675 | 0.76 | ROCK1 (0.43) | KMT2AALDH1A1MEN1MAPTNOTUM | |
| SCHEMBL23131053 | 0.75 | ALDH1A1 (0.53) | KMT2AALDH1A1MEN1USP2CDK4 | |
| SCHEMBL9481934 | 0.75 | MEN1 (0.53) | KMT2AALDH1A1MEN1USP2CDK4 | |
| SCHEMBL9481953 | 0.75 | ALDH1A1 (0.53) | KMT2AALDH1A1MEN1USP2CDK4 | |
| SCHEMBL2344277 | 0.75 | ALDH1A1 (0.53) | KMT2AALDH1A1MEN1USP2CDK4 | |
| SCHEMBL27339784 | 0.73 | NOTUM (0.50) | KMT2AALDH1A1MEN1USP2TSHR | |
| SCHEMBL11643443 | 0.73 | NOTUM (0.49) | NOTUMSMN1; SMN2 | |
| SCHEMBL29625280 | 0.71 | MEN1 (0.54) | KMT2AALDH1A1MEN1USP2CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7351743-B1 | Therapeutic guanidines | WYETH (US) | 2008-04-01 | — | — | US | disclosed |
| US-20070265348-A1 | N-(4-sec-butylphenyl)-N-benzylguanidine; modulate, particularly inhibit, the release of neurotransmitter such as glutamate; neurodegenerative disease: Parkinson's, Huntington's, Alzheimer's diseases, Amyotrophic Lateral Sclerosis, Down's Syndrome, epilepsy, atrophy, HIV | SCION PHARMACEUTICALS, INC, A DELAWARE CORPORATION | 2007-11-15 | — | — | US | disclosed |
| US-6288123-B1 | CENTRAL NERVOUS SYSTEM DISORDERS | CAMBRIDGE NEUROSCIENCES, INC. | 2001-09-11 | — | — | US | disclosed |
| US-6174924-B1 | Therapeutic guanidines | CAMBRIDGE NEUROSCIENCE, INC. | 2001-01-16 | — | — | US | disclosed |
| US-6143791-A | NERVOUS SYSTEM DISORDERS | CAMBRIDGE NEUROSCIENCE, INC. (US) | 2000-11-07 | — | — | US | disclosed |
| EP-0000151-A1 | 1-Substituted aminoindolines, process for their production and pharmaceutical compositions containing them | SANDOZ AG (CH) | 1979-01-10 | — | — | EP | disclosed |
| US-4112111-A | ANTIHYPERTENSIVE | SANDOZ LTD. (CH) | 1978-09-05 | — | — | US | disclosed |
| US-4112111-A | ANTIHYPERTENSIVE | SANDOZ LTD. (CH) | 1978-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265348-A1 | N-(4-sec-butylphenyl)-N-benzylguanidine; modulate, particularly inhibit, the release of neurotransmitter such as glutamate; neurodegenerative disease: Parkinson's, Huntington's, Alzheimer's diseases, Amyotrophic Lateral Sclerosis, Down's Syndrome, epilepsy, atrophy, HIV | GAP43, NLN, HTT | KMT2A 1936/4885ALDH1A1 4175/4885MEN1 3546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.